Gara Jalqabaatti › Luukemiya Limfoositiikii Keessummaa › Pennsylvania › Pittsburgh
Qorannoo klinikaalii Luukemiya Limfoositiikii Keessummaa Pittsburgh, PA keessatti
Qorannoo 10 Luukemiya Limfoositiikii Keessummaa f Pittsburgh fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Namoota walitti qabaa jiraSadarkaa 3
- West Penn Hospital, Pittsburgh
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 3
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Namoota walitti qabaa jiraSadarkaa 3
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Namoota walitti qabaa jiraSadarkaa 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- UPMC Hillman Cancer Center, Pittsburgh
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Pittsburgh
Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- UPMC Hillman Cancer Center, Pittsburgh
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Namoota walitti qabaa jiraSadarkaa 3
- UPMC Hillman Cancer Center, Pittsburgh
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Namoota walitti qabaa jiraSadarkaa 2
- UPMC Hillman Cancer Center, Pittsburgh
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Namoota walitti qabaa jiraSadarkaa 2
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
Qorannoo Luukemiya Limfoositiikii Keessummaa magaalota biroo keessatti
- Boston, MAQorannoo 31
- Columbus, OHQorannoo 28
- Durham, NCQorannoo 27
- Washington, DCQorannoo 22
- Seattle, WAQorannoo 20
- Rochester, MNQorannoo 18
- New York City, NYQorannoo 18
- Houston, TXQorannoo 17
- Baldwin Park, CAQorannoo 16
- Milwaukee, WIQorannoo 15
- Chicago, ILQorannoo 14
- Cincinnati, OHQorannoo 14
Qorannoo biroo Pittsburgh keessatti
- Kansara Qara'a Non-Small CellQorannoo 48
- Saree (Gosoota Hunda)Qorannoo 41
- Saree OljooQorannoo 39
- Kansarii ColorectalQorannoo 32
- Kansara MetastatikiiQorannoo 31
- MelanomaQorannoo 31
- Kansarii OvariiQorannoo 30
- Kansa EndometiriyaaliiQorannoo 23
- Kansarii ProstateQorannoo 23
- Dhibee QaraQorannoo 23
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 22
- StrokeQorannoo 22
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.